Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
Completed · Phase 2
Conditions studied: Pancreatic Cancer
In brief
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of pancreatic cancer by stopping blood flow to the tumor and blocking the enzymes necessary for tumor cell growth. Combining gemcitabine with celecoxib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with celecoxib works in treating patients with metastatic pancreatic cancer.
Key facts
- Study ID
- NCT00068432
- Run by
- M.D. Anderson Cancer Center
- People needed
- 28
- Starts
- 2003-12-01
- Expected to finish
- 2005-07-01
- Last updated by the study team
- 2018-10-31
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Hembree Mercy Cancer Center at St. Edward Mercy Medical Center — Fort Smith, Arkansas, United States
- M.D. Anderson Cancer Center - Orlando — Orlando, Florida, United States
- CCOP - Atlanta Regional — Atlanta, Georgia, United States
- CCOP - Carle Cancer Center — Urbana, Illinois, United States
- CCOP - Wichita — Wichita, Kansas, United States
- CCOP - Kansas City — Kansas City, Missouri, United States
- CCOP - Cancer Research for the Ozarks — Springfield, Missouri, United States
- CCOP - Dayton — Dayton, Ohio, United States
- CCOP - Columbia River Oncology Program — Portland, Oregon, United States
- M.D. Anderson Cancer Center at University of Texas — Houston, Texas, United States
- All Saints Cancer Center at All Saints Healthcare — Racine, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.